CROMA Pharma: healthy and pain-free joints with the help of targeted dietary supplementation and hyaluronic acid therapy

VIENNA--(BUSINESS WIRE)--The natural ageing process, combined with mechanical strain, affects the joints in particular. The result of this wear and tear is a painful restriction of mobility. Today, more than a quarter of people worldwide aged 45-60 are affected by this type of joint disease. Targeted food supplements support the body’s own natural protection mechanisms against cartilage degeneration and contribute towards the overall health of the musculoskeletal system, not only in the elderly.

“The primary treatment objectives are pain relief and improved mobility as the result of increased viscoelasticity of the synovial fluid. The shock-absorbing effect of the hyaluronic acid brings about marked pain relief and improves joint function. In many cases, disease progression can be slowed down.”

If the patient is already experiencing acute problems, viscosupplementation can achieve not only significant pain relief, but also a marked improvement in joint mobility.

Osteoarthritis (a joint disorder mostly affecting the cartilage) is the most common type of degenerative joint disease, affecting a significant portion of the population. 25-30 per cent of people aged between 45 and 60 suffer from this disease. However, even young people can be affected by osteoarthritis, usually after joint injuries. Further risk factors include being overweight, genetic anomalies of the joint cartilage, poor posture or constant overuse of joints, e.g. through sporting activities or heavy physical labour.

Osteoarthritis is associated with a breakdown and the wear and tear of the surface cartilage layer. This results in the bones under the cartilage rubbing together, causing pain and swelling, leading to an impairment of joint mobility. Any joint can be affected, although osteoarthritis is most common in the hand, knee and hip joints and the spine.

SYNOCROM^®: A wide range of viscosupplementation therapy options

Viscosupplementation involves the intra-articular administration of hyaluronic acid preparations. Dr Antje Schebesta: "The primary treatment objectives are pain relief and improved mobility as the result of increased viscoelasticity of the synovial fluid. The shock-absorbing effect of the hyaluronic acid brings about marked pain relief and improves joint function. In many cases, disease progression can be slowed down."

For hyaluronic acid therapy, Croma offers a range of products suitable in particular for knee and hip joints, but also for smaller joints, with the main differences consisting in dosage and the frequency of treatment. Dr Antje Schebesta: "Today there are various viscosupplements available to us, depending on the type and severity of the symptoms. These products are exceptionally well tolerated by the body and provide patients with a significant and sustainable improvement in their quality of live. Their efficacy has been proven in many studies."

SYNOCROM^® is a highly-purified hyaluronic acid produced by bio-fermentation. It is almost identical with the body’s own hyaluronic acid. SYNOCROM^® does not contain preservatives, is exceptionally well tolerated and available in the following types: ¹¹

• SYNOCROM^®
  For all synovial joints
  • 1% hyaluronic acid, bio-fermentative origin
  • Lasting therapeutic effect
  • Contents: 2 ml
• SYNOCROM^® Mini
  For all small synovial joints
  • 1% hyaluronic acid, bio-fermentative origin
  • Lasting therapeutic effect
  • Contents: 1 ml
• SYNOCROM^® Forte
  SYNOCROM^® Forte for the viscosupplementation of large synovial joints takes significantly less time to take effect and lasts longer. Due to its higher concentration, fewer injections are required, reducing the risk of infection.
  • 2% hyaluronic acid, bio-fermentative origin
  • Fast onset of action
  • Significant pain relief (lasting up to 12 months)²
  • Contents: 2 ml
• SYNOCROM^® Forte One
  SYNOCROM^® Forte One is an innovative product for viscosupplementation of the knee, requiring only one injection.
  • 2% hyaluronic acid, bio-fermentative origin
  • Fast onset of action
  • Significant pain relief
  • Pain relief for up to 6 months²
  • Contents: 4 ml

SYNOTABS^® supports natural joint function

Micronutrients, vitamins and minerals naturally accumulate in bone and cartilage. Normally, these substances are absorbed from food. However, in many cases, the body’s own supply of these vital nutrients is not sufficient to keep all joints healthy in the long-term. SYNOTABS^® is a dietary supplement that strengthens joint cartilage, bone and tendons. The well-balanced combination of vital ingredients, including glucosamine sulphate, chondroitin sulphate and a combination of vitamins and minerals (vitamins C and D₃, calcium, manganese), has a positive effect on joint function. Therefore, if taken regularly, SYNOTABS^® increase mobility and support an active lifestyle, at any age.

The renowned Austrian extreme mountain climber and adventurer, Geri Winkler, is a brand ambassador for the SYNOTABS^® nutritional supplement. Even during his extreme tours, he relies on the joint-supporting and joint-protecting effect of SYNOTABS^®.

For further information about joints and osteoarthritis, visit the company’s website: www.gelenkcheck.at. In addition, you can check how healthy your joints are by completing a questionnaire.

Photo text

CRO Fotos Winkler image 1: Geri Winkler relies on Synotabs® during his extreme tours. (Photo credit: CROMA Pharma - media print free of charge) http://db.tt/Y4fDMKtz or

http://db.tt/Nh24iEIh

About CROMA Pharma

CROMA Pharma is a global company based in Austria, dedicated to the development and manufacture of pharmaceuticals and medical devices for ophthalmology, orthopaedics and aesthetic dermatology. CROMA Pharma is one of the 5 top companies worldwide in the field of intraocular lenses and viscoelastics for eye surgery. CROMA Pharma’s success is based on the company’s own research and development efforts. Approximately 56% of sales are related to CROMA Pharma’s own R&D activities which are centred at the company headquarters in Austria. CROMA Pharma is continuously expanding and has offices in Germany, France, Poland, Romania, Spain, Belgium, the Netherlands, the United States and Canada. For further information please visit: http://www.croma.at

¹ CE0123

² Data on file Croma-Pharma GmbH

The original source-language text of this announcement is the official, authoritative version. Translations are provided as an accommodation only, and should be cross-referenced with the source-language text, which is the only version of the text intended to have legal effect.